Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Prostate Cancer treatment details. Chemotherapy. University of Medicine and Dentistry of New Jersey, New Brunswick, New Jersey, United States

Survival: ?
Toxicity Grade: 4
Treatments: Chemotherapy
Drugs: Navelbine
Country: United States
City/State/Province: New Brunswick, New Jersey
Hospital: University of Medicine and Dentistry of New Jersey
Journal: Link
Date: 8/2005

Patients: This Phase II study enrolled 40 men with metastatic hormone-refractory prostate cancer. The mean age was age 70, and 21 had received prior chemotherapy.

Treatment: The treatment involved two chemotherapeutic drugs: docetaxel and vinoelbine. Filgrastim was supplemented to maintain white blood cell production.

Toxicity: The one grade 4 toxicity was neutropenia. Grade 2-3 toxicities included: fatigue, peripheral neuropathy, ataxia, thrombocytopenia, and prolonged clotting time (PT).

Results: 13 of the 40 treated responded to the treatment with a reduction in prostate specific antigen of greater than 50%. Median survival was not reported.

Support: Aventis and Amgen supported this study. Aventis manufactures and markets docetaxel. Amgen manufactures and markets filgrastim. None of the authors disclosed any financial relationships with these companies.

Correspondence: Robert S. DiPaola.

E-mail to a Friend Email Physician More Information